South Africa

The South African Health Products Regulatory Authority (SAHPRA) is the national regulatory body responsible for the evaluation, registration, and post-market surveillance of all health products in South Africa, including medicines, medical devices, in vitro diagnostics, complementary medicines, and clinical trials. SAHPRA was established as an independent juristic person under the South African Health Products Regulatory Authority Act (Act 35 of 2015), which amended the Medicines and Related Substances Act (Act 101 of 1965). All health products must be registered with SAHPRA before they may be marketed, sold, or distributed in South Africa, unless a specific exemption or permit applies. The registration process involves a structured dossier submission, scientific evaluation, and a final administrative decision, with SAHPRA applying a risk-based classification framework to differentiate the depth of review required across product categories.

SAHPRA accepts dossiers compiled according to the Common Technical Document (CTD) format for medicines and aligned international standards for medical devices and diagnostics, including requirements informed by the Global Harmonization Task Force (GHTF) and the International Medical Device Regulators Forum (IMDRF). A local Responsible Person or South African-registered entity is required to act as the legal applicant and post-market contact for all registered products. SAHPRA has undertaken significant institutional reform in recent years, including the introduction of a risk-based medicines evaluation pathway, a backlog reduction programme, and reliance mechanisms that allow expedited review based on approvals from recognised stringent regulatory authorities (SRAs) such as the EMA, US FDA, and TGA. Section 21 permits provide a pathway for unregistered products to be accessed in specific compassionate or emergency use contexts.

Public sector procurement of health products in South Africa is primarily coordinated through the National Department of Health (NDoH) and implemented at both national and provincial levels. The NDoH sets overarching health policy and negotiates national contracts and framework agreements for essential medicines and strategic health commodities through the Central Chronic Medicines Dispensing and Distribution (CCMDD) programme and the National Health Laboratory Service (NHLS) for diagnostic products. Provincial Departments of Health retain significant procurement autonomy and manage their own tender processes through Provincial Tender Boards and Supply Chain Management units, often publishing province-specific bids via the South African Government eTender Portal. The public health system is guided by the Essential Medicines List (EML) and Standard Treatment Guidelines (STGs), and inclusion on these lists is a critical prerequisite for formulary access and public procurement consideration.

The private sector represents a substantial and commercially significant channel in South Africa, served through hospital groups such as Netcare, Mediclinic, and Life Healthcare, as well as retail pharmacy chains and independent practitioners, with procurement often mediated by buying groups and distributors. South Africa also benefits from considerable donor-funded procurement, particularly for HIV, tuberculosis, and malaria programmes, with agencies such as the Global Fund, PEPFAR (via USAID), and UNICEF playing major roles in commodity financing and supply. The NDoH's policy framework encourages local manufacturing and has aligned with the African Union's ambition to increase intra-continental pharmaceutical production, with the South African government actively promoting local production incentives and preferential procurement provisions under the Broad-Based Black Economic Empowerment (B-BBEE) framework and the Preferential Procurement Regulations, which can influence supplier selection in public tenders.